Actr: another new drug declared by FDA

Source: CPHI Pharma online 2017-09-22 on August 23, 2017, the U.S Food and Drug Administration (FDA) approved another ind application of the actr therapy of unum therapeutics, which is combined with the humanized antibody sea-bcma for actr087-t cells to treat recurrent or refractory multiple myeloma Unum expects to begin drug treatment for patients in the first quarter of 2018 In order to provide a suitable dose plan for future clinical research, and to evaluate the response of patients to treatment, as well as the safety and tolerance of sea-bcma At present, another actr087 experiment of the company is currently under phase I trial (nct02776813), which is combined with rituximab for the treatment of relapsed or refractory CD20 positive B-cell non Hodgkin's lymphoma in adult patients What is actr therapy? Actr, or antibody coupled T cell receptor, is a new method to kill cancer cells by using chimeric proteins of receptor binding components in human NK cells and T cells The actr chimeric protein in T cells can bind to an antibody, and then specifically bind to the antigen on the surface of cancer cells, using T cells to attack cancer Actr: the advantages of actr are not limited to a single specific tumor cell antigen compared with other T-cell therapies such as car-t and tcr-t Therefore, it is possible to treat many different types of cancer and promote its application in the treatment of many kinds of cancer Unum's strategy involves using patients' own T cells and modifying them to express an ACRT protein When ACRT is combined with antibodies that can bind to cancer cells, acrt-t cells will play a specific role in killing cancer cells labeled with antibodies In recent years, cancer research has made great progress, but there are still a lot of unmet medical needs in the treatment of diseases, because almost all patients are ultimately difficult to treat The author believes that actr technology, as a new cancer treatment method, has two cancer treatment schemes entering the phase I clinical stage, which is gratifying, but the safety, tolerance and anticancer activity of this treatment method need a lot of clinical trials It's a long way to go, and it will take many years for actr technology to play its advantages in multi-target treatment of cancer